A 20-year Swedish study examines whether youth hospitalized for self-harm face a higher risk of later psychosis. This research update will help you assess whether these patients are at higher risk before more severe illness develops.

Long-acting injectables extend stability in bipolar disorder, delaying relapse more effectively than oral antipsychotics

A history of violence in first-episode schizophrenia may guide antipsychotic selection and influence treatment outcomes.

Recent data sheds light on hallucinogen-related emergency visits.

Lurasidone was heralded as a game changer when it first gained FDA approval for bipolar depression in 2013. In 2023, this article covers what that means for patients with bipolar disorder and schizophrenia who can now afford its $10–$20/month cost.

It’s difficult to find options when clozapine does not work.